Tag Archives: valley
#435260 How Tech Can Help Curb Emissions by ...
Trees are a low-tech, high-efficiency way to offset much of humankind’s negative impact on the climate. What’s even better, we have plenty of room for a lot more of them.
A new study conducted by researchers at Switzerland’s ETH-Zürich, published in Science, details how Earth could support almost an additional billion hectares of trees without the new forests pushing into existing urban or agricultural areas. Once the trees grow to maturity, they could store more than 200 billion metric tons of carbon.
Great news indeed, but it still leaves us with some huge unanswered questions. Where and how are we going to plant all the new trees? What kind of trees should we plant? How can we ensure that the new forests become a boon for people in those areas?
Answers to all of the above likely involve technology.
Math + Trees = Challenges
The ETH-Zürich research team combined Google Earth mapping software with a database of nearly 80,000 existing forests to create a predictive model for optimal planting locations. In total, 0.9 billion hectares of new, continuous forest could be planted. Once mature, the 500 billion new trees in these forests would be capable of storing about two-thirds of the carbon we have emitted since the industrial revolution.
Other researchers have noted that the study may overestimate how efficient trees are at storing carbon, as well as underestimate how much carbon humans have emitted over time. However, all seem to agree that new forests would offset much of our cumulative carbon emissions—still an impressive feat as the target of keeping global warming this century at under 1.5 degrees Celsius becomes harder and harder to reach.
Recently, there was a story about a Brazilian couple who replanted trees in the valley where they live. The couple planted about 2.7 million trees in two decades. Back-of-the-napkin math shows that they on average planted 370 trees a day, meaning planting 500 billion trees would take about 3.7 million years. While an over-simplification, the point is that planting trees by hand is not realistic. Even with a million people going at a rate of 370 trees a day, it would take 83 years. Current technologies are also not likely to be able to meet the challenge, especially in remote locations.
Tree-Bombing Drones
Technology can speed up the planting process, including a new generation of drones that take tree planting to the skies. Drone planting generally involves dropping biodegradable seed pods at a designated area. The pods dissolve over time, and the tree seeds grow in the earth below. DroneSeed is one example; its 55-pound drones can plant up to 800 seeds an hour. Another startup, Biocarbon Engineering, has used various techniques, including drones, to plant 38 different species of trees across three continents.
Drone planting has distinct advantages when it comes to planting in hard-to-access areas—one example is mangrove forests, which are disappearing rapidly, increasing the risk of floods and storm surges.
Challenges include increasing the range and speed of drone planting, and perhaps most importantly, the success rate, as automatic planting from a height is still likely to be less accurate when it comes to what depth the tree saplings are planted. However, drones are already showing impressive numbers for sapling survival rates.
AI, Sensors, and Eye-In-the-Sky
Planting the trees is the first step in a long road toward an actual forest. Companies are leveraging artificial intelligence and satellite imagery in a multitude of ways to increase protection and understanding of forested areas.
20tree.ai, a Portugal-based startup, uses AI to analyze satellite imagery and monitor the state of entire forests at a fraction of the cost of manual monitoring. The approach can lead to faster identification of threats like pest infestation and a better understanding of the state of forests.
AI can also play a pivotal role in protecting existing forest areas by predicting where deforestation is likely to occur.
Closer to the ground—and sometimes in it—new networks of sensors can provide detailed information about the state and needs of trees. One such project is Trace, where individual trees are equipped with a TreeTalker, an internet of things-based device that can provide real-time monitoring of the tree’s functions and well-being. The information can be used to, among other things, optimize the use of available resources, such as providing the exact amount of water a tree needs.
Budding Technologies Are Controversial
Trees are in many ways fauna’s marathon runners—slow-growing and sturdy, but still susceptible to sickness and pests. Many deforested areas are likely not as rich in nutrients as they once were, which could slow down reforestation. Much of the positive impact that said trees could have on carbon levels in the atmosphere is likely decades away.
Bioengineering, for example through CRISPR, could provide solutions, making trees more resistant and faster-growing. Such technologies are being explored in relation to Ghana’s at-risk cocoa trees. Other exponential technologies could also hold much future potential—for instance micro-robots to assist the dwindling number of bees with pollination.
These technologies remain mired in controversy, and perhaps rightfully so. Bioengineering’s massive potential is for many offset by the inherent risks of engineered plants out-competing existing fauna or growing beyond our control. Micro-robots for pollination may solve a problem, but don’t do much to address the root cause: that we seem to be disrupting and destroying integral parts of natural cycles.
Tech Not The Whole Answer
So, is it realistic to plant 500 billion new trees? The short answer would be that yes, it’s possible—with the help of technology.
However, there are many unanswered challenges. For example, many of areas identified by the ETH-Zürich research team are not readily available for reforestation. Some are currently reserved for grazing, others owned by private entities, and others again are located in remote areas or areas prone to political instability, beyond the reach of most replanting efforts.
If we do wish to plant 500 billion trees to offset some of the negative impacts we have had on the planet, we might well want to combine the best of exponential technology with reforestation as well as a move to other forms of agriculture.
Such an approach might also help address a major issue: that few of the proposed new forests will likely succeed without ensuring that people living in and around the areas where reforestation takes place become involved, and can reap rewards from turning arable land into forests.
Image Credit: Lillac/Shutterstock.com Continue reading
Posted in Human Robots
#434792 Extending Human Longevity With ...
Lizards can regrow entire limbs. Flatworms, starfish, and sea cucumbers regrow entire bodies. Sharks constantly replace lost teeth, often growing over 20,000 teeth throughout their lifetimes. How can we translate these near-superpowers to humans?
The answer: through the cutting-edge innovations of regenerative medicine.
While big data and artificial intelligence transform how we practice medicine and invent new treatments, regenerative medicine is about replenishing, replacing, and rejuvenating our physical bodies.
In Part 5 of this blog series on Longevity and Vitality, I detail three of the regenerative technologies working together to fully augment our vital human organs.
Replenish: Stem cells, the regenerative engine of the body
Replace: Organ regeneration and bioprinting
Rejuvenate: Young blood and parabiosis
Let’s dive in.
Replenish: Stem Cells – The Regenerative Engine of the Body
Stem cells are undifferentiated cells that can transform into specialized cells such as heart, neurons, liver, lung, skin and so on, and can also divide to produce more stem cells.
In a child or young adult, these stem cells are in large supply, acting as a built-in repair system. They are often summoned to the site of damage or inflammation to repair and restore normal function.
But as we age, our supply of stem cells begins to diminish as much as 100- to 10,000-fold in different tissues and organs. In addition, stem cells undergo genetic mutations, which reduce their quality and effectiveness at renovating and repairing your body.
Imagine your stem cells as a team of repairmen in your newly constructed mansion. When the mansion is new and the repairmen are young, they can fix everything perfectly. But as the repairmen age and reduce in number, your mansion eventually goes into disrepair and finally crumbles.
What if you could restore and rejuvenate your stem cell population?
One option to accomplish this restoration and rejuvenation is to extract and concentrate your own autologous adult stem cells from places like your adipose (or fat) tissue or bone marrow.
These stem cells, however, are fewer in number and have undergone mutations (depending on your age) from their original ‘software code.’ Many scientists and physicians now prefer an alternative source, obtaining stem cells from the placenta or umbilical cord, the leftovers of birth.
These stem cells, available in large supply and expressing the undamaged software of a newborn, can be injected into joints or administered intravenously to rejuvenate and revitalize.
Think of these stem cells as chemical factories generating vital growth factors that can help to reduce inflammation, fight autoimmune disease, increase muscle mass, repair joints, and even revitalize skin and grow hair.
Over the last decade, the number of publications per year on stem cell-related research has increased 40x, and the stem cell market is expected to increase to $297 billion by 2022.
Rising research and development initiatives to develop therapeutic options for chronic diseases and growing demand for regenerative treatment options are the most significant drivers of this budding industry.
Biologists led by Kohji Nishida at Osaka University in Japan have discovered a new way to nurture and grow the tissues that make up the human eyeball. The scientists are able to grow retinas, corneas, the eye’s lens, and more, using only a small sample of adult skin.
In a Stanford study, seven of 18 stroke victims who agreed to stem cell treatments showed remarkable motor function improvements. This treatment could work for other neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and ALS.
Doctors from the USC Neurorestoration Center and Keck Medicine of USC injected stem cells into the damaged cervical spine of a recently paralyzed 21-year-old man. Three months later, he showed dramatic improvement in sensation and movement of both arms.
In 2019, doctors in the U.K. cured a patient with HIV for the second time ever thanks to the efficacy of stem cells. After giving the cancer patient (who also had HIV) an allogeneic haematopoietic (e.g. blood) stem cell treatment for his Hodgkin’s lymphoma, the patient went into long-term HIV remission—18 months and counting at the time of the study’s publication.
Replace: Organ Regeneration and 3D Printing
Every 10 minutes, someone is added to the US organ transplant waiting list, totaling over 113,000 people waiting for replacement organs as of January 2019.
Countless more people in need of ‘spare parts’ never make it onto the waiting list. And on average, 20 people die each day while waiting for a transplant.
As a result, 35 percent of all US deaths (~900,000 people) could be prevented or delayed with access to organ replacements.
The excessive demand for donated organs will only intensify as technologies like self-driving cars make the world safer, given that many organ donors result from auto and motorcycle accidents. Safer vehicles mean less accidents and donations.
Clearly, replacement and regenerative medicine represent a massive opportunity.
Organ Entrepreneurs
Enter United Therapeutics CEO, Dr. Martine Rothblatt. A one-time aerospace entrepreneur (she was the founder of Sirius Satellite Radio), Rothblatt changed careers in the 1990s after her daughter developed a rare lung disease.
Her moonshot today is to create an industry of replacement organs. With an initial focus on diseases of the lung, Rothblatt set out to create replacement lungs. To accomplish this goal, her company United Therapeutics has pursued a number of technologies in parallel.
3D Printing Lungs
In 2017, United teamed up with one of the world’s largest 3D printing companies, 3D Systems, to build a collagen bioprinter and is paying another company, 3Scan, to slice up lungs and create detailed maps of their interior.
This 3D Systems bioprinter now operates according to a method called stereolithography. A UV laser flickers through a shallow pool of collagen doped with photosensitive molecules. Wherever the laser lingers, the collagen cures and becomes solid.
Gradually, the object being printed is lowered and new layers are added. The printer can currently lay down collagen at a resolution of around 20 micrometers, but will need to achieve resolution of a micrometer in size to make the lung functional.
Once a collagen lung scaffold has been printed, the next step is to infuse it with human cells, a process called recellularization.
The goal here is to use stem cells that grow on scaffolding and differentiate, ultimately providing the proper functionality. Early evidence indicates this approach can work.
In 2018, Harvard University experimental surgeon Harald Ott reported that he pumped billions of human cells (from umbilical cords and diced lungs) into a pig lung stripped of its own cells. When Ott’s team reconnected it to a pig’s circulation, the resulting organ showed rudimentary function.
Humanizing Pig Lungs
Another of Rothblatt’s organ manufacturing strategies is called xenotransplantation, the idea of transplanting an animal’s organs into humans who need a replacement.
Given the fact that adult pig organs are similar in size and shape to those of humans, United Therapeutics has focused on genetically engineering pigs to allow humans to use their organs. “It’s actually not rocket science,” said Rothblatt in her 2015 TED talk. “It’s editing one gene after another.”
To accomplish this goal, United Therapeutics made a series of investments in companies such as Revivicor Inc. and Synthetic Genomics Inc., and signed large funding agreements with the University of Maryland, University of Alabama, and New York Presbyterian/Columbia University Medical Center to create xenotransplantation programs for new hearts, kidneys, and lungs, respectively. Rothblatt hopes to see human translation in three to four years.
In preparation for that day, United Therapeutics owns a 132-acre property in Research Triangle Park and built a 275,000-square-foot medical laboratory that will ultimately have the capability to annually produce up to 1,000 sets of healthy pig lungs—known as xenolungs—from genetically engineered pigs.
Lung Ex Vivo Perfusion Systems
Beyond 3D printing and genetically engineering pig lungs, Rothblatt has already begun implementing a third near-term approach to improve the supply of lungs across the US.
Only about 30 percent of potential donor lungs meet transplant criteria in the first place; of those, only about 85 percent of those are usable once they arrive at the surgery center. As a result, nearly 75 percent of possible lungs never make it to the recipient in need.
What if these lungs could be rejuvenated? This concept informs Dr. Rothblatt’s next approach.
In 2016, United Therapeutics invested $41.8 million in TransMedics Inc., an Andover, Massachusetts company that develops ex vivo perfusion systems for donor lungs, hearts, and kidneys.
The XVIVO Perfusion System takes marginal-quality lungs that initially failed to meet transplantation standard-of-care criteria and perfuses and ventilates them at normothermic conditions, providing an opportunity for surgeons to reassess transplant suitability.
Rejuvenate Young Blood and Parabiosis
In HBO’s parody of the Bay Area tech community, Silicon Valley, one of the episodes (Season 4, Episode 5) is named “The Blood Boy.”
In this installment, tech billionaire Gavin Belson (Matt Ross) is meeting with Richard Hendricks (Thomas Middleditch) and his team, speaking about the future of the decentralized internet. A young, muscled twenty-something disrupts the meeting when he rolls in a transfusion stand and silently hooks an intravenous connection between himself and Belson.
Belson then introduces the newcomer as his “transfusion associate” and begins to explain the science of parabiosis: “Regular transfusions of the blood of a younger physically fit donor can significantly retard the aging process.”
While the sitcom is fiction, that science has merit, and the scenario portrayed in the episode is already happening today.
On the first point, research at Stanford and Harvard has demonstrated that older animals, when transfused with the blood of young animals, experience regeneration across many tissues and organs.
The opposite is also true: young animals, when transfused with the blood of older animals, experience accelerated aging. But capitalizing on this virtual fountain of youth has been tricky.
Ambrosia
One company, a San Francisco-based startup called Ambrosia, recently commenced one of the trials on parabiosis. Their protocol is simple: Healthy participants aged 35 and older get a transfusion of blood plasma from donors under 25, and researchers monitor their blood over the next two years for molecular indicators of health and aging.
Ambrosia’s founder Jesse Karmazin became interested in launching a company around parabiosis after seeing impressive data from animals and studies conducted abroad in humans: In one trial after another, subjects experience a reversal of aging symptoms across every major organ system. “The effects seem to be almost permanent,” he said. “It’s almost like there’s a resetting of gene expression.”
Infusing your own cord blood stem cells as you age may have tremendous longevity benefits. Following an FDA press release in February 2019, Ambrosia halted its consumer-facing treatment after several months of operation.
Understandably, the FDA raised concerns about the practice of parabiosis because to date, there is a marked lack of clinical data to support the treatment’s effectiveness.
Elevian
On the other end of the reputability spectrum is a startup called Elevian, spun out of Harvard University. Elevian is approaching longevity with a careful, scientifically validated strategy. (Full Disclosure: I am both an advisor to and investor in Elevian.)
CEO Mark Allen, MD, is joined by a dozen MDs and Ph.Ds out of Harvard. Elevian’s scientific founders started the company after identifying specific circulating factors that may be responsible for the “young blood” effect.
One example: A naturally occurring molecule known as “growth differentiation factor 11,” or GDF11, when injected into aged mice, reproduces many of the regenerative effects of young blood, regenerating heart, brain, muscles, lungs, and kidneys.
More specifically, GDF11 supplementation reduces age-related cardiac hypertrophy, accelerates skeletal muscle repair, improves exercise capacity, improves brain function and cerebral blood flow, and improves metabolism.
Elevian is developing a number of therapeutics that regulate GDF11 and other circulating factors. The goal is to restore our body’s natural regenerative capacity, which Elevian believes can address some of the root causes of age-associated disease with the promise of reversing or preventing many aging-related diseases and extending the healthy lifespan.
Conclusion
In 1992, futurist Leland Kaiser coined the term “regenerative medicine”:
“A new branch of medicine will develop that attempts to change the course of chronic disease and in many instances will regenerate tired and failing organ systems.”
Since then, the powerful regenerative medicine industry has grown exponentially, and this rapid growth is anticipated to continue.
A dramatic extension of the human healthspan is just over the horizon. Soon, we’ll all have the regenerative superpowers previously relegated to a handful of animals and comic books.
What new opportunities open up when anybody, anywhere, and at anytime can regenerate, replenish, and replace entire organs and metabolic systems on command?
Join Me
Abundance-Digital Online Community: I’ve created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is my ‘onramp’ for exponential entrepreneurs – those who want to get involved and play at a higher level. Click here to learn more.
Image Credit: Giovanni Cancemi / Shutterstock.com Continue reading
Posted in Human Robots